[Long-term results of 60Co HDR after-loading in the treatment of cervical cancer].
From Jan. 1981 to Dec. 1986, 1053 patients with cervical cancer were treated with Cobalt-60 high dose-rate afterloading therapy (Ralstron-20B). All cases have been followed up over 5 years. This paper analysed the 5-year survival rates and complications of cervical carcinoma treated with high dose-rate afterloading therapy. According to the point A dosage, the whole series was divided into four groups: group A 141 patients (65Gy/6 wks), group B 130 patients (60Gy/6 wks), group C 243 patients (55Gy/6 wks) and group D 539 patients (50Gy/5 wks). The dosage of external irradiation in four groups was the same. The 5-year survival rates of the four groups were little better than that of the conventional radium-treated group. The incidence of late rectal and bladder reactions in group D was lower than that in group A B C or radium-treated group. These results indicate that the point A dosage of 50Gy/5 wks (dose rate about 100cGy/min) is suitable in HDR intracavitary afterloading therapy of cervical cancer.
Wang
X E
XE
Cancer Hospital, Shanghai Medical University, Shanghai.
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011879:Radiotherapy Dosage; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes